Iovance COO granted 117,500 RSUs

BILINSKY IGOR reported acquisition or exercise transactions in this Form 4 filing.

Accepted by SEC EDGAR 03/11/2026 - 05:00 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

BILINSKY IGOR reported acquisition or exercise transactions in this Form 4 filing.

Iovance Biotherapeutics reported that Chief Operating Officer Igor Bilinsky received a grant of 117,500 restricted stock units. Each RSU represents one share of common stock. The award vests over three years, with one-third vesting after one year and the balance in eight quarterly installments.

Insider Trade Summary

Grant/Award: 117,500 shares

Grant/Award 1 txn

Insider BILINSKY IGOR

Role Chief Operating Officer

Type	Security	Shares	Price	Value
Grant/Award	Restricted Stock Units	117,500	$0.00	$0.00

Holdings After Transaction: Restricted Stock Units — 117,500 contracts (Direct)

Holdings Before and After: Restricted Stock Units, 0 to 117,500 contracts (Direct)

Footnotes (2)

1. F1. Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.
2. F2. Provided the Reporting Person is still employed with the Issuer on the following dates, the RSUs shall vest over three years, with (i) one-third of the RSUs vesting on the one-year anniversary of the date of grant and (ii) the remaining RSUs shall vest in eight equal quarterly installments over the next two years, commencing with the first quarter following the first anniversary of the date of grant.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did IOVANCE BIOTHERAPEUTICS (IOVA) report on this Form 4?

The filing reports a grant of 117,500 restricted stock units to Chief Operating Officer Igor Bilinsky. These RSUs are a form of equity compensation that can convert into common shares if vesting conditions based on continued employment are satisfied over time.

Who is the insider receiving RSUs in IOVANCE BIOTHERAPEUTICS (IOVA)?

The recipient is Igor Bilinsky, the Chief Operating Officer of Iovance Biotherapeutics. He received 117,500 restricted stock units as a compensation award, giving him a contingent right to receive common stock if he remains employed through the vesting schedule.

How do the 117,500 RSUs granted by IOVANCE BIOTHERAPEUTICS (IOVA) vest?

The 117,500 RSUs vest over three years. One-third vests on the first anniversary of the grant date, and the remaining two-thirds vest in eight equal quarterly installments over the following two years, assuming continued employment at each vesting date.

Does the IOVANCE BIOTHERAPEUTICS (IOVA) Form 4 show an open-market stock purchase or sale?

No, the transaction is a grant of restricted stock units, not an open-market trade. The Form 4 uses code A, indicating an award or other acquisition of derivative securities as compensation rather than a discretionary market buy or sell.

What does each RSU granted by IOVANCE BIOTHERAPEUTICS (IOVA) represent?

Each restricted stock unit represents a contingent right to receive one share of Iovance’s common stock. Shares are only delivered if the vesting conditions are met, tying the COO’s compensation to future service and the company’s long-term equity value.

How many IOVANCE BIOTHERAPEUTICS (IOVA) shares could result from this RSU grant?

If all vesting conditions are met, the 117,500 restricted stock units could convert into 117,500 shares of Iovance common stock. Delivery of shares occurs over three years as the RSUs vest based on the COO’s continued employment.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

BILINSKY IGOR

(Last) (First) (Middle)

C/O IOVANCE BIOTHERAPEUTICS, INC.

825 INDUSTRIAL ROAD, SUITE 100

(Street)

SAN CARLOS CA 94070

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
IOVANCE BIOTHERAPEUTICS, INC. [ IOVA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Operating Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/09/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	03/09/2026		A		117,500		(2)	(2)	Common stock	117,500	$0.00	117,500	D

Explanation of Responses:

1. Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.

2. Provided the Reporting Person is still employed with the Issuer on the following dates, the RSUs shall vest over three years, with (i) one-third of the RSUs vesting on the one-year anniversary of the date of grant and (ii) the remaining RSUs shall vest in eight equal quarterly installments over the next two years, commencing with the first quarter following the first anniversary of the date of grant.

	/s/ Igor Bilinsky	03/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.